Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:52:05.494Z.
Calculation as of: 2026-10-06T22:52:05.494Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5b41231b7583dd96ab78187317b9f32b3728f458d8f95d0d00832bd8f136f307
PE RATIO
N/A
Neumora Therapeutics, Inc. Common Stock
Market Cap
$87.27M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $87.27M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | N/A | 3.67 | 3.67 | 3.67 |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 29.66 | 45.53 | 45.53 | 24.63 |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $89.78M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 117.85 | 46.83 | 44.28 | 282.12 |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.64M | 2.19 | 2.16 | 2.16 | 2.16 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.47
Forward EPS (Est.)
$-0.91
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
